Dual effect of nicotine in inflammatory diseases
AktualitaGastroent Hepatol 2024; 78(3): 270–271.
LiteraturepdfKulatý stůl: Subkutánní infliximab v léčbě IBD a terapeutické monitorování hladin léčiva v praxi
AktualitaGastroent Hepatol 2023; 77(2): 147–153. doi: 10.48095/ccgh2023147
Literaturepdf Karin ČernáTofacitinib – is it time for a change in treatment in ulcerative colitis?
AktualitaGastroent Hepatol 2023; 77(1): 78–81.
pdf Kateřina MichnováSecondary failure of biological treatment – a major challenge for biobetters
AktualitaGastroent Hepatol 2022; 76(5): 458–462.
pdf Kateřina MichnováThat’s how time passed with PBC – it is necessary to move one step forward again
AktualitaGastroent Hepatol 2022; 76(4): 359–363.
pdf Kateřina MichnováSubcutaneous Infliximab – the beginning of the era of biobetters in the treatment of immune-mediated inflammatory diseases
AktualitaGastroent Hepatol 2022; 76(3): 268–271.
pdf Kateřina MichnováTelemedicine is more than a „doctor on the phone“
AktualitaGastroent Hepatol 2021; 75(3): 263–265. doi: 10.48095/ccgh2021263
pdf Kateřina Michnová